Loading...
Market
How many Alzheimer's patients will be diagnosed using blood tests in primary care by December 31, 2025?
2
Resolution / Starting Odds
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Healthcare data analytics reports
Story
New Blood Test Shows 90% Accuracy in Diagnosing Alzheimer's Disease at AAIC 2024
Jul 28, 2024, 12:15 PM
A new blood test has shown promise in diagnosing Alzheimer's disease with 90% accuracy, outperforming traditional cognitive tests and CT scans. This development represents a significant step forward in affordable diagnosis of the condition. The test, presented at the Alzheimer's Association International Conference (AAIC) 2024, could improve diagnosis in primary care, making testing more accessible and less invasive. It also provides a quicker path to research participation and treatment. The study results have been validated by the FNIH Biomarkers Consortium and published in JAMA. The PrecivityAD2™ blood test by C2N Diagnostics has markedly improved accuracy in both primary care and specialized memory care. Sunbird Bio has also presented data reinforcing the significance of blood-based tau biomarkers in the accurate diagnosis of Alzheimer's disease. Acumen Pharmaceuticals presented patient experience and biomarker data from Phase 1 INTERCEPT-AD study at AAIC 2024.
View original story
Similar markets
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
0-10 • 25%
11-20 • 25%
21-30 • 25%
31 or more • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%
0-10 • 25%
11-50 • 25%
51-100 • 25%
More than 100 • 25%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,000 to 30,000 • 25%
More than 30,000 • 25%
0-1000 • 25%
1001-5000 • 25%
5001-10000 • 25%
10001+ • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
0-10 providers • 25%
11-20 providers • 25%
21-30 providers • 25%
More than 30 providers • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
